MDHearing VoltMax vs Resound Vivia 9 60S microRIE

The MDHearing VoltMax is a behind-the-ear OTC hearing aid priced at $699, earning a B grade with a SoundScore of 3.0/5 in our lab testing. This mid-priced device ranks #62 of 65 in the OTC Hearing Aid category, placing it in the bottom portion of tested products. In our standardized testing, the VoltMax demonstrates excellent feedback handling at 5.0/5, scoring 0.46 points above the category average. This means users are unlikely to experience whistling or squealing during typical wear. However, speech performance presents significant challenges—speech in quiet scores a low 1.9/5 (0.93 points below average), while speech in noise scores 1.0/5 (0.48 points below average). These results suggest limited benefit for understanding conversation in both calm and challenging listening environments. Music streaming is a notable weakness, scoring 0.0/5 and falling 1.92 points below the category average. Users who prioritize streaming audio content from their phones should consider alternatives. Own-voice comfort is mixed at 2.4/5, roughly matching the category average. At this price point, several alternatives offer substantially stronger performance. Devices like the Yeasound RIC800 and Sony CRE-E10 score above 4.5/5 at similar or lower prices. The VoltMax may appeal to users who prioritize feedback-free wear and basic amplification with rechargeable convenience, but those seeking stronger speech clarity should explore higher-performing options in this price range.

The Resound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, currently available at $3,798. In HearAdvisor's lab testing, it earned a B grade with a SoundScore of 3.9/5, ranking #27 of 36 prescription hearing aids tested. This device demonstrates a mixed performance profile in our testing. Own-voice comfort is a notable strength, scoring 3.4/5—a solid result that sits 0.65 points above the category average, which may appeal to users sensitive to the hollow or boomy sound of their own speech. Speech clarity in quiet environments also performs well at 3.4/5, slightly above the category average. However, the Vivia 9 shows significant limitations in challenging listening situations. Speech in noise scored just 1.1/5, falling 0.81 points below the prescription hearing aid average—a substantial gap that suggests difficulty in restaurants, group conversations, or other noisy environments. Feedback handling, while strong in absolute terms at 4.2/5, still lands 0.51 points below what we typically see from prescription devices. Music streaming quality is mixed at 2.6/5, essentially matching the category average. At this premium price point, the Vivia 9 faces stiff competition. Several same-priced alternatives, including the Phonak Sphere Infinio and Oticon Intent, achieved notably higher overall scores in our testing. Consumers prioritizing noise performance may want to explore these options or consider lower-priced alternatives like the Sennheiser All Day Clear that delivered stronger overall results in our lab.